IMEXF (Imagin Medical) Cyclically Adjusted PB Ratio: (As of Jul. 08, 2026)


What is Imagin Medical Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Imagin Medical  (OTCPK:IMEXF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Imagin Medical Cyclically Adjusted PB Ratio Related Terms


Imagin Medical Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Imagin Medical's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imagin Medical Cyclically Adjusted PB Ratio Chart

Imagin Medical Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.11 0.07 0.10 0.12

Imagin Medical Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.12 0.12 0.16 0.00

IMEXF vs ABT, SYK, MDT: Cyclically Adjusted PB Ratio Comparison

For the Medical Devices subindustry, Imagin Medical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imagin Medical Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Imagin Medical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Imagin Medical's Cyclically Adjusted PB Ratio falls into.



Imagin Medical Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Imagin Medical's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Imagin Medical's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book=Book Value per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.831/124.2033*124.2033
=-0.831

Current CPI (Jun. 2023) = 124.2033.

Imagin Medical Quarterly Data

Book Value per Share CPI Adj_Book
201309 11.134 97.419 14.195
201312 10.387 96.945 13.308
201403 9.490 98.604 11.954
201406 7.794 99.473 9.732
201409 1.062 99.394 1.327
201412 0.541 98.367 0.683
201503 0.082 99.789 0.102
201506 -0.258 100.500 -0.319
201509 -0.041 100.421 -0.051
201512 -0.055 99.947 -0.068
201603 0.327 101.054 0.402
201606 0.177 102.002 0.216
201609 0.046 101.765 0.056
201612 0.057 101.449 0.070
201703 -0.057 102.634 -0.069
201706 -0.141 103.029 -0.170
201709 -0.165 103.345 -0.198
201712 0.329 103.345 0.395
201803 0.557 105.004 0.659
201806 0.818 105.557 0.962
201809 0.687 105.636 0.808
201812 0.589 105.399 0.694
201903 0.493 106.979 0.572
201906 0.371 107.690 0.428
201909 0.229 107.611 0.264
201912 0.095 107.769 0.109
202003 0.072 107.927 0.083
202006 0.030 108.401 0.034
202009 -0.028 108.164 -0.032
202012 -0.075 108.559 -0.086
202103 -0.268 110.298 -0.302
202106 -0.309 111.720 -0.344
202109 -0.984 112.905 -1.082
202112 -0.976 113.774 -1.065
202203 -1.078 117.646 -1.138
202206 -0.697 120.806 -0.717
202209 -0.923 120.648 -0.950
202212 -0.905 120.964 -0.929
202303 -0.957 122.702 -0.969
202306 -0.831 124.203 -0.831

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Imagin Medical Business Description

Address 890 West Pender Street, Suite 600, Vancouver, BC, CAN, V6C 1J9
Imagin Medical Inc is a Urologic Oncology company developing technologies to visualize and treat urologic cancers, including bladder and prostate cancer, through minimally invasive surgery. The company's first product, the i/Blue Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting bladder cancer, helping to improve the surgical management of this disease. Imagin's follow-on product, the enCAGE Coil is a device with 510(k) clearance for soft tissue ablation. Imagin intends to refine the disposable bipolar radio frequency-based probe for use in the treatment of prostate cancer and benign prostate hypoplasia (BPH) and submit appropriate FDA premarket applications for the new indications.